🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

442 results for “Institut” Clear

  1. Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

    The George Institute

    Untreated small triple negative breast cancer

    phase 2 other active

    1 trial

  2. Sibeprenlimab, Sibeprenlimab placebo

    Otsuka Beijing Research Institute

    Treatment of Sjögren’s disease

    phase 2 small molecule active

    1 trial

  3. Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vector

    The George Institute

    Recessive dystrophic epidermolysis bullosa (RDEB)

    phase 2 small molecule active

    1 trial

  4. Sodium Chloride Injection/ DEMO 0,9% w/v, EMAPALUMAB

    The George Institute

    SEPSIS

    phase 2 small molecule active

    1 trial

  5. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  6. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    chronic limb-threatening ischemia, diabetic foot ulcers

    phase 2 small molecule active

    1 trial

  7. Sustanon 250, solution injectable

    The George Institute

    Androgen deficiency, palliative care

    phase 2 small molecule active

    1 trial

  8. TAZEMETOSTAT, IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  9. TEMOZOLOMIDE

    The George Institute

    Diffuse low-grade gliomas

    phase 2 small molecule active

    1 trial

  10. TEMOZOLOMIDE VIATRIS 5 mg, gélule, Capivasertib, TEMOZOLOMIDE VIATRIS 100 mg, gélule, VINORELBINE ACCORD 20 mg, capsule molle, Votubia 3 mg dispersible tablets, Bavencio 20 mg/mL concentrate for solution for infusion, Peposertib, INC280, Enasidenib Mesilate, Futibatinib, TEMOZOLOMIDE VIATRIS 20 mg, gélule, Capivasertib, VINORELBINE ACCORD 30 mg, capsule molle, INC280, Enasidenib Mesilate, Votubia 5 mg dispersible tablets, Votubia 2 mg dispersible tablets, Capivasertib

    The George Institute

    pediatric cancer

    phase 2 small molecule active

    1 trial

  11. THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion

    The George Institute

    haematological malignancies

    phase 2 small molecule active

    1 trial

  12. TNG462, S095035 tablet 25mg, S095035 tablet 50mg, TNG462, TNG462

    The George Institute

    MTAP-deleted advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  13. TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion, VINCRISTINE HOSPIRA 2 mg/2 ml, solution injectable, Etoposide 20 mg/ml concentrate for solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, MELPHALAN TILLOMED 50 mg/10 mL, poudre et solvant pour solution injectable / pour perfusion, Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion

    The George Institute

    Ocular conservative treatment for retinoblastoma

    phase 2 small molecule active

    1 trial

  14. TRASTUZUMAB EMTANSINE, Herceptin 150 mg powder for concentrate for solution for infusion, 89Zr-Trastuzumab_IJB

    The George Institute

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 small molecule active

    1 trial

  15. TREMELIMUMAB, DURVALUMAB

    The George Institute

    MSS and MSI colorectal and endometrial tumors

    phase 2 small molecule active

    1 trial

  16. TRIPTORELIN, GONAPEPTYL 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée en seringues pré-remplies., LEUPRORELIN ACETATE, BAY 1841788, TRIPTORELIN, DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, DEGARELIX, LEUPRORELIN ACETATE

    The George Institute

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  17. Tarlatamab, Tarlatamab

    The George Institute

    Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)

    phase 2 small molecule active

    1 trial

  18. Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Locally advanced cervical cancer

    phase 2 small molecule active

    1 trial

  19. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.

    phase 2 small molecule active

    1 trial

  20. Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    The George Institute

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial

  21. Tecentriq 1 200 mg concentrate for solution for infusion, Pulmocis 2 mg trousse pour préparation radiopharmaceutique, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Non resectable Hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  22. Temozolomide Accord 5 mg hard capsules., Temozolomide ratiopharm 20 mg, capsules, hard, Temozolomide ratiopharm 250 mg, capsules, hard, Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 180 mg hard capsules, Temozolomide Accord 140 mg hard capsules., TEMOZOLOMIDE VIATRIS 180 mg, gélule, Temozolomide ratiopharm 180 mg, capsules, hard, Temozolomide SUN 5 mg hard capsules, TEMOZOLOMIDE VIATRIS 140 mg, gélule, Temozolomide Accord 20 mg hard capsules, Temozolomide Accord 180 mg hard capsules., S95032/AG-88

    The George Institute

    IDH1-mutant Glioma, IDH2-mutant Glioma

    phase 2 small molecule active

    1 trial

  23. TolDec

    The George Institute

    Multiple sclerosis

    phase 2 small molecule active

    1 trial

  24. Tumor Intiltrating Lymphocytes (TIL) – VHIO, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, Melanoma Tumor Intiltrating Lymphocytes (TIL) – NKI, Fludarabine - PCH 25 mg/ml, concentraat voor oplossing voor intraveneuze infusie of injectie, ANV419, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Genoxal 1.000 mg polvo para solución inyectable y para perfusión, PROLEUKIN, 18x106 UI polvo para solución inyectable o para perfusión, PROLEUKIN®

    The George Institute

    Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources